Portable and accurate diagnostics for COVID-19: Combined use of the miniPCR® thermocycler and a well-plate reader for SARS-Co2 virus detection

Everardo González-González[1,2], Grissel Trujillo-de Santiago[1,3], Itzel Montserrat Lara-Mayorga[1,2], Sergio Omar Martínez-Chapa[3], Mario Moisés Alvarez[1,2*]

[1] Centro de Biotecnología-FEMSA, Tecnologico de Monterrey, CP 64849, Monterrey, Nuevo León, México

[2] Departamento de Bioingeniería, Tecnologico de Monterrey, CP 64849, Monterrey, Nuevo León, México

[3] Departamento de Ingeniería Mecátrónica y Eléctrica, Tecnologico de Monterrey, CP 64849, Monterrey, Nuevo León, México

*Corresponding authors. E-mails: mario.alvarez@tec.mx

Abstract

The COVID-19 pandemic has crudely demonstrated the value of massive and rapid diagnostics. By the first week of April, more than 900,000 positive cases of COVID-19 have been reported worldwide, although this number could be greatly underestimated. In

the case of an epidemic emergency, the first line of response should be based on commercially available and validated resources. Here, we demonstrate the combined use of the miniPCR®, a commercial compact and portable PCR device recently available on the market, and a commercial well-plate reader as a diagnostic system for detecting SARS-CoV2 nucleic acids. We used the miniPCR to detect and amplify SARS-CoV2 DNA sequences using the sets of initiators recommended by the World Health Organization for targeting three different regions that encode for the N protein. Prior to amplification, samples were combined with a DNA intercalating reagent (i.e., EvaGreen® Dye). Sample fluorescence after amplification was then read using a commercial 96-well plate reader. This straightforward method allows the detection and amplification of SARS-CoV2 nucleic acids in the range of ~625 to 2×10^5 DNA copies. The accuracy and simplicity of this diagnostics strategy may provide a cost-efficient and reliable alternative for COVID-19 pandemic testing, particularly in underdeveloped regions where RT-QPCR instrument availability may be limited. In addition, the portability, ease of use, and reproducibility of the miniPCR® makes it a reliable alternative for deployment in point-of-care SARS-CoV2 detection efforts during pandemics.

Key words: mini-PCR, point-of-care, SARS-CoV2, COVID-19, diagnostic, portable, nucleic acid amplification

Introduction

The development of cost-efficient diagnostic point-of-care (POC) systems for the opportune diagnosis of infectious diseases has been recognized as a niche of high relevance

[1,2]. The recent pandemic/epidemic episodes associated with viral diseases (e.g., pandemic Influenza A/H1N1/2009 [3], Ebola in West Africa in 2013-2015 [4], and Zika in Southeast Asia and Latin-America in 2016 [5,6]) were clear reminders of the need for portable, low-cost, and easy-to-use diagnostic systems that can effectively address epidemic episodes in remote or underprivileged areas [7–10]. Nevertheless, the COVID-19 pandemic has broadsided most countries, with only a few (i.e., South Korea [11], China, Singapore [12], and Taiwan [13]) showing an ability to deploy massive efforts for rapid and accurate detection of positive infection cases. The swift and massive testing of thousands of possibly infected subjects has been an important component of the strategy of these countries that has helped to effectively mitigate the spreading of COVID-19 among their populations [11,13,14].

Many methodologies have been proposed to deliver cost-effective and accurate diagnosis (i.e., methods based on immunoassays or specific gene hybridization [15,16]); however, nucleic acid amplification, and particularly real-time quantitative PCR (RT-qPCR), continues to be the gold standard for the detection of viral diseases in early stages [17,18]. For example, for the last two pandemic events involving influenza A/H1N1/2009 and COVID-19 [19], the Centers for Disease Control (CDC) and the World Health Organization (WHO) recommended RT-qPCR methods as the gold standard for official detection of positive cases. Unfortunately, conducting RT-qPCR diagnostics often depends on access to centralized laboratory facilities for testing [20–22]. To resolve this drawback, multiple studies have proposed and validated the use of compact PCR-based methods and devices for POC settings [23,24]. However, during epidemic episodes, resourcing of

incompletely developed technologies is impractical and leaves commercially available diagnostic platforms as the first line of defense in epidemiological emergencies.

The first wave of miniaturized PCR machines has only recently become commercially available [25]. The miniPCR® from Amplyus (MA, USA) was one of the earliest highly compact PCR units on the international market [26]. The original miniPCR® units reached the marketplace in 2015, with an approximate cost of $600 USD (versus $3000 USD for a conventional PCR thermocycler) [25], but only a few papers have been published that have addressed validation of the use of miniPCR® systems as diagnostic tools [27–31].

We recently published a comparison of the performance of the miniPCR and a commercial thermal cycler for the identification of artificial Zika and Ebola genetic sequences. Our experiments using a wide variety of primers sets and template concentrations revealed no differences in performance between either thermal cycler type [32]. The commercial availability, low price (as compared to conventional thermocyclers), portability, and user friendliness of the miniPCR® make it an attractive and tangible solution that effectively brings PCR analysis to the POC. In the present study, we demonstrate the convenience of using the miniPCR® (www.minipcr.com) for the detection and amplification of synthetic samples of SARS-CoV2 [19], the causal viral agent of the current COVID-19 pandemic.

Materials and Methods

Equipment specifications: We ran equivalent sets of amplification experiments in a miniPCR from Amplyus (MA, USA). The unit has dimensions of 20 × 5 × 15 cm, weighs

0.7 kg, and requires 120V (AC) and 3.5 A to operate. The miniPCR can run 8 amplifications in parallel.

A commercial power supply (PowerPac from Bio-Rad, CA, USA) was used to operate the electrophoresis unit used to run the agarose gels to reveal the amplification products obtained by the miniPCR thermocycler. A Bio-Rad ChemiDoc XRS imaging system was used for end-point PCR detection. Alternatively, the miniPCR unit has its own blueGel electrophoresis unit (Figure 1 A, B), powered by 120 V AC, and photo-documentation can be done using a smartphone camera.

We also used a Synergy HT microplate reader (BioTek Instruments, VT, USA) to detect the fluorescence induced by an intercalating reagent in positive samples from the PCR reactions.

Controls for validation

We used a plasmid containing the complete N gene from 2019-nCoV, SARS, and MERS as positive controls at a concentration of 200,000 copies/µL (Integrated DNA Technologies, IA, USA). Samples containing different concentrations of synthetic nucleic acids of SARS-CoV2 were prepared by successive dilutions from stocks containing 200,000 copies mL^{-1} ng/L of viral nucleic acids. We used a plasmid containing the GP gene from Ebola Virus (EBOV) as a negative control. The production of this EBOV genetic material has been documented previously by our group [32].

Amplification mix: We used REDTaq Ready Mix from Sigma-Aldrich (USA), and followed the recommended protocol: 10 µL Readymix, 0.5 µM of forward primer, 0.5 µM of reverse primer,1µL of DNA template (~ 625 to $2x10^5$ DNA copies), 1µl of EvaGreen® Dye, and nuclease free water to final volume of reaction 20 µL.



Figure 1. **Equipment and initiators for SARS-Co2 detection using a miniPCR**. A) The miniPCR® thermocycler. (B) The blueGel® electrophoresis chamber: blueGel® allows visualization of a 15 ml agarose gel using an integrated blue LED array. (C) Agarose gel electrophoresis of the SARS-CoV2 amplification products. (D) Commercial 96-well plate with COVID-19 controls (artificial DNA samples). (E) Temperature cycling scheme used in our PCR protocol. (F) Three different sets of primers were used to target a gene sequence encoding the SARS-Co2 N protein.

Primers used:

Three different sets of primers were used to target three different regions of the SARS-Co2 N gene sequence. These primer sets are identical to those recommended by the Center of Disease Control (CDC) for the standard diagnostics of COVID-19 (i.e., N1, N2, and N3 assays) using quantitative real time PCR. Sequences of all these primers and their corresponding amplicons are presented in Table 1 and 2.

Table 1. Primer sequences used in PCR amplification experiments

Name	**Description**	**Primers Sequence (5'>3')**
2019-nCoV_N1-F	2019-nCoV_N1 Forward Primer	5'-GAC CCC AAA ATC AGC GAA AT-3'
2019-nCoV_N1-R	2019-nCoV_N1 Reverse Primer	5'-TCT GGT TAC TGC CAG TTG AAT CTG-3'
2019-nCoV_N2-F	2019-nCoV_N2 Forward Primer	5'-TTA CAA ACA TTG GCC GCA AA-3'
2019-nCoV_N2-R	2019-nCoV_N2 Reverse Primer	5'-GCG CGA CAT TCC GAA GAA-3'
2019-nCoV_N3-F	2019-nCoV_N3 Forward Primer	5'-GGG AGC CTT GAA TAC ACC AAA A-3'
2019-nCoV_N3-R	2019-nCoV_N3 Reverse Primer	5'-TGT AGC ACG ATT GCA GCA TTG-3'

Table 2. Amplicon sequences generated (and their corresponding lengths) by each of the primer pairs used in the PCR amplification experiments (see also Fig XX).

Primer pair	**Amplicon sequence**	**Amplicon Length (nt)**
N1	GACCCCAAAATCAGCGAAATGCACCCCGCATTACGTTTG GTGGACCCTCAGATTCAACTGGCAGTAACCAGA	72
N2	TTACAAACATTGGCCGCAAATTGCACAATTTGCCCCCAGC GCTTCAGCGTTCTTCGGAATGTCGCGC	67
N3	GGGAGCCTTGAATACACCAAAAGATCACATTGGCACCCG CAATCCTGCTAACAATGCTGCAATCGTGCTACA	72

Amplification protocols: For all PCR experiments, we used the same three-stage protocol (see Fig 1D) consisting of a denaturation stage at 94℃ for 5 min, followed by 25 cycles of 94 °C for 20s, 60 °C for 30s, and 72 °C for 20s, and then a final stage at 72 °C for 5 min, for a total duration of 60 minutes in the miniPCR® thermocycler.

Documentation of PCR products: We analyzed 10 μL of each PCR product using 2% agarose electrophoresis in Tris-acetic acid-EDTA (TAE) buffer (Sigma-Aldrich, MO, USA). Gels were dyed with GelGreen (Biotium, CA, USA) using a 1:10,000 dilution and a current of 110 V supplied by a Bio-Rad PowerPac HC power supply (Bio-Rad, CA, USA) for 40 min. We used the Quick-Load Purple 2-Log DNA ladder (NEB, MA, USA) as a molecular weight marker. We analyzed the gels by UV transillumination using a Bio-Rad ChemiDoc XRS imaging system.

In some of our experiments, we also used the blueGel unit, a portable electrophoresis unit sold by MiniPCR from Amplyus (MA, USA). This is a compact electrophoresis unit (23 × 10 × 7 cm) that weighs 350 g. In these experiments, we analyzed 10 μL of PCR product using 2% agarose electrophoresis tris-borate-EDTA buffer (TBE). Gels were dyed with Gel- Green (CA, USA) using a 1:10,000 dilution, and a current of 48 V was supplied by the blueGel built-in power supply (AC 100–240 V, 50–60 Hz).

As a third method of detection and to read the amplification product, we evaluated the amplification products by detecting the fluorescence emitted by a DNA intercalating agent, the EvaGreen® Dye, in the Synergy HT microplate reader (BioTek Instruments, VT, USA). Briefly, 20 μL of the PCR reaction mix was placed in distinct wells of a 96-well plate, after completion of the PCR program. Each well was made to a final volume of 150 μL by adding 130 μL of nuclease free water and the samples were well mixed by pipetting. These

experiments were run in triplicate. The following conditions were used in the microplate reader: excitation of 485/20, emission of 528/20, gain of 75. Fluorescence readings were made from the above at room temperature.

Results and Discussion

An actual epidemic emergency does not provide the required timeframe for testing new diagnostic strategies; therefore, the first line of response must be based on commercially available and validated resources [32,33]. Here, we demonstrate that the combined use of a commercial and portable PCR unit (the miniPCR) and a 96-well plate reader is potentially adequate for the fast deployment of diagnostic efforts in the context of COVID-19 pandemics. We show the combined ability of both units to amplify and identify different synthetic genetic sequences of SARS-CoV2 (see Materials and Methods).

Analysis of sensitivity

We conducted a series of experiments to assess the sensitivity of the PCR reactions conducted in the miniPCR thermocycler using the three sets of primers recommended by CDC to diagnose infection by SARS-CoV2. Table 1 shows the sets of primers used to target genetic sequences that code for the expression of the SARS-CoV2 N protein. Table 2 shows the sequence of the DNA products (amplicons) generated by successful targeting of these regions with the N1, N2, and N3 primer pairs.

Figures 2A-C show the PCR products of the amplification reactions conducted using three different primer pairs. In all cases, different concentrations of SARS-CoV2 genetic material, in the range of 2.0×10^5 to 625 DNA copies, were used as reaction templates. If

we put this range in the proper clinical context, the actual viral load of COVID-19 in nasal swabs from patients has been estimated to fall within the range of 10^5 to 10^6 viral copies per mL [19]. The amplification proceeds with sufficient quality to allow proper visualization of the amplification products in electrophoresis gels, even at low nucleic acid concentrations. Figure 2A-C shows agarose gels containing the amplification products of each one of three experiments, where the three different sets of primers (namely N1, N2, and N3) were used to amplify the same range of concentrations of template. The miniPCR® was able to generate a visible band of amplification products for all three primer sets and across the whole range of synthetic viral loads.

Conventionally, the products of amplification in final point PCR are primarily detected on agarose gels using conventional electrophoresis techniques conducted with conventional lab equipment. However, as previously mentioned, the miniPCR® system is commercialized with its own "blueGel®" electrophoretic unit (Figure 1B-C). The blueGel® has several important advantages: it is fully portable, its size allows optimization of reagent usage (agarose gel 15 mL, buffer 25 mL), the built-in power supply allows visualization of band separation in real time (this can shorten the electrophoretic time by up to 5 minutes), and exposure to ethidium bromide and UV light is completely avoided by the use of GelGreen® dye and detection with blue light. Therefore, the blueGel system represents a valid and portable solution for detecting PCR amplification products. Nevertheless, running an experiment aimed at visualizing amplification products, as with any standard gel electrophoresis procedure, requires time. A good separation of bands typically involves a processing time of 35 to 60 minutes from the loading of the amplification product to the final documentation through photography.

As an alternative, we show here that the amount of amplification product can be quantitatively evaluated using a commercial 96-well plate reader. To do this, we used an intercalating agent during amplification in the miniPCR apparatus. Figure 2a shows the fluorescence readings associated with the analysis of the different dilutions of synthetic SARS-CoV2 samples previously revealed by gel electrophoresis. We ran triplicate reactions for each dilution and for each primer data set. The fluorescence readings were capable of clearly discriminating between positive and negative samples across the whole range of dilutions tested (from 2×10^5 to 625 copies). This observation holds true for each of the three primer sets tested. Note that the use of a plate reader, instead of a conventional gel electrophoresis unit, presupposes a significant savings in time. Up to 96 PCR reactions can be read in a matter of 5 to 10 minutes. This implies that an array of 12 miniPCR units and a plate reader could equal the throughput of a traditional RT-QPCR platform, but at one third of the capital cost. In addition, during emergencies and particularly in developing countries, attaining or buying regular thermal cyclers and plate readers is much easier than purchasing or accessing RT-qPCR systems.

In addition, our results suggest that fluorescence readings using a plate reader exhibit high reproducibility and robustness. Overall, we obtained small standard deviations (in the range of 6 to 40 arbitrary fluorescence units [a.f.u.]) and a small average variance coefficient (2.6%) in fluorescence readings across the whole range of values of viral copies tested. We observed similar variability indicators in experiments using different primer pairs. For instance, we observed variance coefficients of 2.31%, 2.15%, and 3.34% when using primer sets N1, N2, and N3, respectively. If we considered only fluorescence readings from positive samples, we observed variance coefficients of 2.23%, 2.34%, and 1.31% when using primer sets N1, N2, and N3, respectively.



Figure 2. Evaluation of the sensitivity of the combined use of a miniPCR® thermal cycler (for amplification) and a plate reader (for determination of the amplification extent). (A-C) Sensitivity trials using different concentrations of the template (positive control) and three different primers sets (A) N1, indicated in blue; (B) N2, indicated in red; and (C) N3, indicated in yellow. Images of agarose gel electrophoresis of the DNA amplification product generated by targeting three different regions of the sequence coding for SARS-Co2 N protein. PCR was performed using a miniPCR® thermocycler. Three different primer sets were used (N1, N2, and N3). The initial template amount was gradually increased from left to right: molecular weight ladder (lane 1), negative control (lane 2), 625 copies (lane 3), 2.5×10^3 (lane 4), 1.0×10^4 (lane 5), 4.0×10^4 (lane 6), 2.0×10^5 DNA copies (lane 7). (D-F) Determination of fluorescence, as measured in a commercial plate reader, for

different dilutions of SARS-CoV2 synthetic DNA templates. Results using three different primer sets are shown: (A) N1, indicated in blue; (B) N2, indicated in red; and (C) N3, indicated in yellow. (G) Summary and comparison of fluorescence readings form synthetic samples of SARS-CoV2 in a wide span of dilutions. Results using three different primer sets are shown: (A) N1, indicated in blue; (B) N2, indicated in red; and (C) N3, indicated in yellow.

Figure 2G consolidates the fluorescence readings obtained from miniPCR amplifications using synthetic SARS-CoV2 samples and the primer sets N1 (blue bars), N2 (red bars), and N3 (yellow bars). Overall, this data set is consistent. These results suggest that any of the primer sets tested (N1, N2, or N3) may be used to amplify SARS-CoV2 genetic material in the miniPCR. However, for the experimental conditions tested (i.e., the nature and concentration of the intercalating agent, the concentrations of primers, and the concentration of enzyme, among others), we observe differences in the performance of each primer pair. For example, primer sets N1 and N3 appear to promote amplifications in which the observed fluorescence is proportional to the initial concentration of DNA template (i.e., the viral load). By contrast, primer pair N2 appears to generate amplification product with high fluorescence emissions even at low values of the initial final copy numbers. Note that all fluorescence readings for positive samples shown in Figure 2E exhibit a fluorescence reading between 1300 and 1400 a.f.u.

Furthermore, measuring the fluorescence with the plate reader may add a quantitative element to the analysis of positive COVID-19 samples. In principle, samples with higher viral loads will exhibit higher fluorescence if processed through the same PCR program (i.e., exposed to the same number of cycles). For example, for amplifications using primer set N3, we observe a linear relationship between the natural logarithm of the number of viral copies and the natural logarithm of fluorescence signal for the range of 625 to 40,000

viral copies:

$$\text{Ln (viral load)} = \alpha * \text{Ln}(F_{sample} - F_o) \quad (1)$$

where F_o is the fluorescence reading exhibited by a blank (i.e., a negative sample prepared and processed in the same way than the positive samples) and $\alpha = 8.897$ (as determined by fitting of the data presented in Figure 2C). For instance, we believe we can adjust the concentration of intercalating reagent to assure linearity of the fluorescence signal with respect to the viral load for experiments with different primer sets. This simple strategy will result in a fully quantitative, reliable, and easily implemented quantitative version of a straightforward final-point PCR protocol.



Figure 3. Potential use of a plate reader for quantitation of the initial viral load in a sample and the extent of amplification. (A) Linear relationship between the natural logarithm of the fluorescence reading and the natural logarithm of the viral load. (B) Results of the simulation of real time PCR in a microplate reader.

Using the primers and methods described here, we were able to consistently detect the presence of SARS-CoV2 synthetic DNA using a miniPCR and a simple plate reader. In the current context of the COVID-19 pandemics, the importance of communicating this result

does not reside in its novelty but in its practicality. In our experiments, we have used the three sets of primers designed and recommended by the CDC to identify the presence of SARS-CoV2, the causal agent of COVID-19. These primer pairs, aimed at identifying three different regions encoding for the N protein of SARS-CoV2, have been widely validated and used for diagnostic purposes in actual COVID-19 patients, Here we simply translated widely tested protocols from the framework of an RT-qPCR apparatus (the gold standard platform recommended for analyzing and confirming positive cases) to execution in a miniaturized and already commercial POC thermal cycler. While the cost of a commercial RT-qPCR apparatus falls in the range of $10,000 to $40,000 USD, the commercial value of the miniPCR is under $800 USD. This difference is significant, especially when considering the need for rational investment of resources during an epidemic crisis.

While the quantitative capabilities of testing in a RT-QPCR platform are undisputable, the capacity of many countries for rapid, effective, and massive establishment of diagnostic centers based on RT-qPCR is questionable. The current pandemic scenarios experienced in the USA, Italy, France, and Spain, among others, have crudely demonstrated that centralized labs are not an ideal solution during emergencies. Portable diagnostic systems may provide the required flexibility and speed of response that RT-qPCR platforms cannot deliver.

To further illustrate the deterministic and quantitative dependence between the concentration of amplification product and the fluorescence signal, as measured in a plate reader, we simulated some real-time amplification experiments. To that end, we conducted amplification reactions using initial amounts of 4×10^4 copies of synthetic SARS-CoV2 in the miniPCR cycler. We added the intercalating agent, EvaGreen® Dye, to the reaction mix at the initial time and extracted samples after 1, 5, 10, 15, 20, 25, and 30 PCR cycles. The

fluorescence from these samples was then measured in a plate reader. We observed a linear increase in fluorescence as more PCR cycles were performed, which highlights the quantitative nature of the intercalating reaction.

Our results suggest that using a commercial plate reader to determine the extent of advance of PCR amplifications is a practical, reliable, reproducible, and robust alternative to the use of gel electrophoresis. Moreover, fluorescence reading of PCR products may lead to precise quantification of viral loads.

Conclusions

The challenge of POC detection of viral threats is of paramount importance, particularly in underdeveloped regions and in emergency situations (i.e., natural disasters or epidemic outbreaks). In the context of an emergency, time is very limited (as are other resources) to conduct research or develop new technologies; therefore, the use of commercially available and tested technologies is an obvious first countermeasure. Our research extends the validation of the miniPCR technology to the as yet unexplored topic of detection of COVID-19.

We used the set of primers developed by the CDC and recommended by the WHO for conducting the standard PCR diagnostics of COVID-19. These primers target three different regions of the viral nucleic acids encoding for the N protein. In our experiments, we corroborate that the miniPCR apparatus is capable of amplifying small amounts of SARS-CoV2 synthetic nucleic acids. We were able to detect and amplify 64 copies of genes encoding for the N protein of SARS-CoV2.

The use of the miniPCR® is intuitive and simple; the user can easily follow the advance of the iterative temperature cycling using a laptop. Despite its compact size, the miniPCR® allows the performance of a full amplification protocol in a similar time as achieved with a conventional thermocycler. The mini-PCR® thermocycler exhibits the essential attributes of a POC system: (a) the use of small volumes, (b) low capital cost, (c) portability, (d) and a fast, accurate, and selective response.

Moreover, the combined use of the miniPCR thermocycler and a 96-well plate reader enables the possibility of obtaining immediate readings of the amplification products, thereby providing faster (and potentially quantitative) diagnostic results in shorter times than when gel electrophoresis techniques are used. Therefore, the combined use of these already two commercially available devices—a miniPCR thermocycler and a 96-well plate reader—has great potential for use during epidemic emergencies.

Acknowledgments

EGG acknowledges funding from a doctoral scholarship provided by CONACyT (Consejo Nacional de Ciencia y Tecnología, México). GTdS and MMA acknowledge the institutional funding received from Tecnológico de Monterrey (Grant 002EICIS01), and funding provided by CONACyT (Consejo Nacional de Ciencia y Tecnología, México) through grants (SNI 26048, SNI 256730, and Scholarships 635891, 856068, and 814593).

Supporting Information

Excel data file S1: Excel file that contains raw data

References

1. Yager P, Domingo GJ, Gerdes J. Point-of-Care Diagnostics for Global Health. Annu Rev Biomed Eng. Annual Reviews ; 2008;10: 107–144. doi:10.1146/annurev.bioeng.10.061807.160524
2. Alvarez MM, Aizenberg J, Analoui M, Andrews AM, Bisker G, Boyden ES, et al. Emerging Trends in Micro- and Nanoscale Technologies in Medicine: From Basic Discoveries to Translation. ACS Nano. American Chemical Society; 2017;11: 5195–5214. doi:10.1021/acsnano.7b01493
3. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, et al. Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans. N Engl J Med. Massachussetts Medical Society; 2009;360: 2605–2615. doi:10.1056/NEJMoa0903810
4. Kaushik A, Tiwari S, Dev Jayant R, Marty A, Nair M. Towards detection and diagnosis of Ebola virus disease at point-of-care. Biosensors and Bioelectronics. Elsevier Ltd; 2016. pp. 254–272. doi:10.1016/j.bios.2015.08.040
5. Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika Virus. Baden LR, editor. N Engl J Med. Massachussetts Medical Society; 2016;374: 1552–1563. doi:10.1056/NEJMra1602113
6. Fauci AS, Morens DM. Zika Virus in the Americas — Yet Another Arbovirus Threat. N Engl J Med. Massachussetts Medical Society; 2016;374: 601–604. doi:10.1056/NEJMp1600297
7. Mauk MG, Song J, Bau HH, Liu C. Point-of-Care Molecular Test for Zika Infection. Clin Lab Int. NIH Public Access; 2017;41: 25–27. Available:

http://www.ncbi.nlm.nih.gov/pubmed/28819345

8. Kaushik A, Tiwari S, Dev Jayant R, Marty A, Nair M. Towards detection and diagnosis of Ebola virus disease at point-of-care. Biosens Bioelectron. NIH Public Access; 2016;75: 254–72. doi:10.1016/j.bios.2015.08.040

9. Jansen van Vuren P, Grobbelaar A, Storm N, Conteh O, Konneh K, Kamara A, et al. Comparative Evaluation of the Diagnostic Performance of the Prototype Cepheid GeneXpert Ebola Assay. J Clin Microbiol. American Society for Microbiology; 2016;54: 359–67. doi:10.1128/JCM.02724-15

10. Duchesne L, Lacombe K. Innovative technologies for point-of-care testing of viral hepatitis in low-resource and decentralized settings. J Viral Hepat. John Wiley & Sons, Ltd (10.1111); 2018;25: 108–117. doi:10.1111/jvh.12827

11. Cohen J, Kupferschmidt K. Countries test tactics in “war” against COVID-19. Science. American Association for the Advancement of Science; 2020;367: 1287–1288. doi:10.1126/science.367.6484.1287

12. Pung R, Chiew CJ, Young BE, Chin S, I-C Chen M, Clapham HE, et al. Articles Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures. Lancet. Elsevier; 2020;19: 1–8. doi:10.1016/S0140-6736(20)30528-6

13. Wang CJ, Ng CY, Brook RH. Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing. JAMA - Journal of the American Medical Association. American Medical Association; 2020. doi:10.1001/jama.2020.3151

14. Salathé M, Althaus CL, Neher R, Stringhini S, Hodcroft E, Fellay J, et al. COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and

isolation. Swiss Med Wkly. EMH Media; 2020;150: w20225. doi:10.4414/smw.2020.20225

15. Alvarez MM, López-Pacheco F, Aguilar-Yañez JM, Portillo-Lara R, Mendoza-Ochoa GI, García-Echauri S, et al. Specific Recognition of Influenza A/H1N1/2009 Antibodies in Human Serum: A Simple Virus-Free ELISA Method. Jeyaseelan S, editor. PLoS One. Public Library of Science; 2010;5: e10176. doi:10.1371/journal.pone.0010176

16. Yen C-W, de Puig H, Tam JO, Gómez-Márquez J, Bosch I, Hamad-Schifferli K, et al. Multicolored silver nanoparticles for multiplexed disease diagnostics: distinguishing dengue, yellow fever, and Ebola viruses. Lab Chip. The Royal Society of Chemistry; 2015;15: 1638–1641. doi:10.1039/C5LC00055F

17. Nguyen Van JC, Caméléna F, Dahoun M, Pilmis B, Mizrahi A, Lourtet J, et al. Prospective evaluation of the Alere i Influenza A&B nucleic acid amplification versus Xpert Flu/RSV. Diagn Microbiol Infect Dis. Elsevier Inc.; 2016;85: 19–22. doi:10.1016/j.diagmicrobio.2015.11.012

18. Murphy J, Bustin SA. Reliability of real-time reverse-transcription PCR in clinical diagnostics: gold standard or substandard? Expert Rev Mol Diagn. Taylor & Francis; 2009;9: 187–197. doi:10.1586/14737159.9.2.187

19. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA - Journal of the American Medical Association. American Medical Association; 2020. doi:10.1001/jama.2020.3786

20. Kozel TR, Burnham-Marusich AR. Point-of-Care Testing for Infectious Diseases: Past, Present, and Future. J Clin Microbiol. American Society for Microbiology; 2017;55: 2313–2320. doi:10.1128/JCM.00476-17

21. Su W, Gao X, Jiang L, Qin J. Microfluidic platform towards point-of-care diagnostics in infectious diseases. J Chromatogr A. Elsevier; 2015;1377: 13–26. doi:10.1016/J.CHROMA.2014.12.041

22. Drancourt M, Michel-Lepage A, Boyer S, Raoult D. The Point-of-Care Laboratory in Clinical Microbiology. Clin Microbiol Rev. American Society for Microbiology; 2016;29: 429–47. doi:10.1128/CMR.00090-15

23. Qiu X, Ge S, Gao P, Li K, Yang S, Zhang S, et al. A smartphone-based point-of-care diagnosis of H1N1 with microfluidic convection PCR. Microsyst Technol. Springer Berlin Heidelberg; 2017;23: 2951–2956. doi:10.1007/s00542-016-2979-z

24. Petralia S, Conoci S. PCR technologies for point of care testing: Progress and perspectives. ACS Sensors. American Chemical Society; 2017. pp. 876–891. doi:10.1021/acssensors.7b00299

25. Marx V. PCR heads into the field. Nat Methods. 2015;12: 393–397. doi:10.1038/nmeth.3369

26. Kwon H-S, Park H-C, Lee K, An S, Oh Y-L, Ahn E-R, et al. Performance of MiniPCR ™ mini8, a portable thermal cycler. Anal Sci Technol. The Korean Society of Analytical Science; 2016;29: 79–84. doi:10.5806/AST.2016.29.2.79

27. Guevara EE, Frankel DC, Ranaivonasy J, Richard AF, Ratsirarson J, Lawler RR, et al. A simple, economical protocol for DNA extraction and amplification where there is no lab. Conserv Genet Resour. Springer Netherlands; 2018;10: 119–125. doi:10.1007/s12686-017-0758-5

28. Pomerantz A, Peñafiel N, Arteaga A, Bustamante L, Pichardo F, Coloma LA, et al. Real-time DNA barcoding in a rainforest using nanopore sequencing: opportunities for rapid biodiversity assessments and local capacity building. Gigascience. Oxford

University Press; 2018;7. doi:10.1093/gigascience/giy033

29. Boguraev A-S, Christensen HC, Bonneau AR, Pezza JA, Nichols NM, Giraldez AJ, et al. Successful amplification of DNA aboard the International Space Station. npj Microgravity. 2017;3. doi:10.1038/s41526-017-0033-9

30. Montague TG, Almansoori A, Gleason EJ, Copeland DS, Foley K, Kraves S, et al. Gene expression studies using a miniaturized thermal cycler system on board the International Space Station. Reddy S V., editor. PLoS One. Public Library of Science; 2018;13: e0205852. doi:10.1371/journal.pone.0205852

31. Zaky WI, Tomaino FR, Pilotte N, Laney SJ, Williams SA. Backpack PCR: A point-of-collection diagnostic platform for the rapid detection of Brugia parasites in mosquitoes. McCarthy JS, editor. PLoS Negl Trop Dis. Public Library of Science; 2018;12: e0006962. doi:10.1371/journal.pntd.0006962

32. Gonzá Lez-Gonzá Lez E, Mendoza-Ramos JL, Pedrozaid SC, Cuellar-Monterrubio A, Má Rquez-Ipiña AR, Lira-Serhanid D, et al. Validation of use of the miniPCR thermocycler for Ebola and Zika virus detection. 2019; doi:10.1371/journal.pone.0215642

33. Chin CD, Linder V, Sia SK. Commercialization of microfluidic point-of-care diagnostic devices{. doi:10.1039/c2lc21204h


A
minipcr


B
bluegel


C

D
C
D
E
F
G


Step 1
94°C
5 min
Step 2
94°C
20 s
60°C
30 s
Step 3
72°C
20 s
72°C
5 min
25 cycles
E


F
1
N Gene
1260
N1: 72 nt
N3: 72 nt
N2: 67 nt
2019-nCoV_N3 Forward Primer
1
100
200
300
400
500
600
700
800
900
1,000
1,100
1,200
1,260
N CDS
2019-nCoV_N1 Forward Prime
F3
B3
2019-nCoV_N2 Reverse Primer
2019-nCoV_N1 Reverse Primer
2019-nCoV_N3 Reverse Primer
2019-nCoV_N2 Forward Primer


A
1 2 3 4 5 6 7
B
1 2 3 4 5 6 7
C
1 2 3 4 5 6 7
D
N1 set
F (a.f.u.)
1600
1400
1200
1000
800
600
400
0.0E+00
6.3E+02
2.5E+03
1.0E+04
4.0E+04
2.0E+05
Number of viral copies
E
N2 set
F (a.f.u.)
1600
1400
1200
1000
800
600
400
0.0E+00
6.3E+02
2.5E+03
1.0E+04
4.0E+04
2.0E+05
Number of viral copies
F
N3 set
F (a.f.u.)
1800
1600
1400
1200
1000
800
600
400
Negative
625
2.5x103
1x104
4x104
2x105
Number of viral copies
G
N1
N2
N3
F (a.f.u.)
1800
1600
1400
1200
1000
800
600
400
200
0
Negative
625
2.5X10³
1.0X10⁴
4.0X10⁴
2.0X10⁵
Number of viral copies


A
y = 8.897x - 51.224
R² = 0.984
Ln (Viral load)
12
11
10
9
8
7
6
6.4
6.6
6.8
7
Ln (F-F$_o$)


B
y = 86.429x + 873.86
R² = 0.9714
F (a.f.u.)
1600
1500
1400
1300
1200
1100
1000
900
1
5
10
15
20
25
30
Number of PCR cycles